Amneal Gains US FDA Approval for Prolia and XGEVA Denosumab Biosimilars
The US FDA approvals for Prolia and XGEVA denosumab biosimilars strengthen Amneal’s growing biosimilars portfolio, with the company planning to commercialise six biosimilars across eight presentations by 2027.
Amneal Pharmaceuticals | 23/12/2025 | By News Bureau | 177
Amneal Gets FDA Approval for Epinephrine Vials
The FDA has approved Amneal’s epinephrine injection in both single- and multi-dose vials, strengthening the company’s injectables portfolio with a critical medicine widely used in hospitals for emergency and perioperative care.
Amneal Pharmaceuticals | 10/12/2025 | By Akanki | 118
Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma
BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.
Amneal Pharmaceuticals | 07/04/2025 | By Aishwarya | 247
Amneal Secures FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Propofol is an intravenous drug commonly used in hospitals for the induction and maintenance of anesthesia and sedation.
Amneal Pharmaceuticals | 21/08/2024 | By Aishwarya | 611
Amneal Pharma Gets US FDA Approval for CREXONT Extended-Release Capsules
CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets.
Amneal Pharmaceuticals | 08/08/2024 | By Aishwarya | 887
Amneal Expands Broad Injectables Portfolio with Addition of Six New Therapies
Amneal Pharmaceuticals has expanded its injectables portfolio with six new injectable product launches during the second quarter of 2024.
Amneal Pharmaceuticals | 11/06/2024 | By Aishwarya | 563
Delegation from HHS and FDA Visit Amneal Manufacturing Site in India
The visit followed the G20 Health Ministers' meeting in Gandhinagar, India, where health ministers from around the world met to discuss global health issues.
Amneal Pharmaceuticals | 01/09/2023 | By Manvi | 1088
Amneal Pharma begins commercial operations in India
Appoints Shyamakant Giri as Managing Director and President for India Business and Emerging Markets
Amneal Pharmaceuticals | 10/10/2022 | By Sudeep Soparkar | 1339
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy